ArticleScientific reports2023
Bacteriophages with depolymerase activity in the control of antibiotic resistant Klebsiella pneumoniae biofilms.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Phage vB_KpnM_NB cocktail synergizing with amikacin in inhibiting persister cells ofApplied and environmental microbiology · 2026Article
- Genomic characterization of novel lytic bacteriophages targeting carbapenemase producing multidrug resistant Klebsiella pneumoniae from Ethiopia: a molecular study.BMC microbiology · 2026Article
- Harnessing lytic phages for biofilm control in carbapenem-resistantMicrobiology spectrum · 2026Article
- Transkingdom Interactions Between Viruses and Bacteria: Implications for Wastewater Treatment Efficiency.Food and environmental virology · 2026Review
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Genome characterization and receptor-binding protein identification of Klebsiella phage vB_VIPKPNMC05, a member of a novel viral family Pituviridae.Archives of virology · 2026Article
- Evaluation of bacteriophage efficacy against Pseudomonas aeruginosa in ex vivo and in vitro canine skin systems.Scientific reports · 2026Article
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
- Next-Generation Strategies for Controlling Foodborne Pathogens: Precision Antimicrobials, Biofilm Disruption, and Emerging Molecular Interventions.Foods (Basel, Switzerland) · 2026Review
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- Carbapenem-resistant Acinetobacter baumannii bloodstream infections and specific phages isolation, analysis and application.Frontiers in cellular and infection microbiology · 2026Article
- Phage enabled precision drug delivery: dual function platforms for therapeutics and genetic cargo transport.Frontiers in microbiology · 2026Review
- Genomic and virulence characterization of OXA-48-producingFrontiers in microbiology · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Genomic and functional characterization of a novel halophilic bacteriophage targeting carbapenem-resistant Klebsiella pneumoniae.PloS one · 2026Article
- Viral Dark Matter: Illuminating Protein Function, Ecology, and Biotechnological Promises.Biochemistry · 2025Review
- Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Phage vB_KpnM_JYSS3 encodes a novel polysaccharide depolymerase that exhibits specific activity against K2-type carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2025Article
- Isolation and identification of bacteriophage against Escherichia coli ATCC 25922 and their biofilm Inhibition studies.Scientific reports · 2025Article
- Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.International urogynecology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella pneumoniae is associated with a variety of infections, such as pneumonia, urogenital infection, liver abscess, and bloodstream infection. It is especially dangerous for patients in medical facilities, where it can cause ventilator-associated pneumonia or intensive care unit-acquired pneumonia. The emergence of multidrug-resistant and hypervirulent strains as well as the ability to form biofilms on various medical devices complicates the treatment of such infections and makes the use of antibiotics ineffective. The application of bacteriophages is a promising alternative for combating Klebsiella pneumoniae biofilms. In the present study a cocktail of 3 bacteriophages with depolymerase activity was used to control antibiotic resistant Klebsiella pneumoniae biofilms in vitro. Biofilms were examined using optical and scanning electron microscopy. The obtained results demonstrate that the studied bacteriophage cocktail can effectively disrupt Klebsiella pneumoniae biofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.